Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,493)	$ (6,744)	$ (15,893)	$ (20,428)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation for property, plant and equipment			105	307
Amortization of intangible assets			662	674
Reduction in the carrying amount of the right-of-use assets			643	687
Loss / (gain) on disposal of property, plant and equipment				65
Stock-based compensation expense			3,831	3,038
Acquired in-process research and development				6,555
Change in fair value of investments	1,153	(1,914)	2,708	(3,482)
Impairment loss of long-term investments		865		865
Changes in operating assets and liabilities:
Accounts receivable			(457)	(1,122)
Inventories			(3,884)	(2,119)
Prepaid expenses and other assets			257	352
Accounts payable			236	884
Accrued and other current liabilities and other liabilities			(1,895)	(1,592)
Deferred income			(34)	(25)
Net cash used in operating activities			(13,721)	(15,341)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposal of property and equipment			138
Purchases of property, plant and equipment			(1,719)	(1,208)
Cash paid to acquire in-process research and development				(6,250)
Net cash used in investing activities			(3,249)	(13,044)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from bank borrowings			1,001	709
Repurchase of common stock			(3,000)
Stock issuance costs				(2,019)
Proceeds from sale of common stock				32,500
Net cash (used in) provided by financing activities			(1,999)	31,190
Effect of exchange rate change on cash and cash equivalents			(873)	488
Net (decrease)/ increase in cash and cash equivalents			(19,842)	3,293
Cash and cash equivalents at beginning of period			38,704	57,064	$ 57,064
Cash and cash equivalents at end of period	$ 18,862	$ 60,357	18,862	60,357	$ 38,704
Non-cash investing and financing activities:
Purchases of property, plant and equipment in accrued and other current liabilities			469
Accrual for acquisition of in-process research and development				305
Black Belt Tx Limited
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire convertible loan				(86)
Cleave Therapeutics, Inc
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire convertible loan				$ (5,500)
BioInvent International AB
CASH FLOWS FROM INVESTING ACTIVITIES
Proceed from sale of equity securities			1,294
Precision Autoimmune Therapeutics Co., Ltd
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire equity securities			$ (2,962)